Brief: New Data Show Hookipa’S Arenaviral Immunotherapies Induce Potent T Cell Responses In Novel Combinations And Against Tumor Self-Antigens
13/04/2022 16:02
HOOKIPA Pharma Inc HOOK.O :
* NEW DATA SHOW HOOKIPA’S ARENAVIRAL IMMUNOTHERAPIES INDUCE
POTENT
T CELL RESPONSES IN NOVEL COMBINATIONS AND AGAINST TUMOR
SELF-ANTIGENS
* HOOKIPA PHARMA INC - CLINICAL UPDATE ON PHASE 1 HB-200
MONOTHERAPY DATA IS ANTICIPATED MID-YEAR
Source text for Eikon: ID:nGNX3gPc4Z
Further company coverage: HOOK.O
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)